Encourage appropriate (not food-related) rewards for when the child or young person meets a goal. Unmet goals can be viewed as opportunities for families to learn more about their situation, including the barriers they face to achieving their goals. Five key behavioural tools are: self-monitoring, stimulus control, problem solving, contingency management or contracting, cognitive restructuring. See Appendix 1 for more information on these tools. Other options for weight management Weight management support services and programmes Weight management services and programmes range from nutrition and healthy-eating services to exercise and weight-loss programmes. Some such services are publicly funded, through the Ministry of Health or DHBs. The types of services available vary throughout the country. Ideally, they should have input from a multidisciplinary team. Examples of relevant services and programmes include: dietetic services whānau planning services Whānau Ora providers and collectives work to support whānau – aspirations by helping whānau to set goals and creating a pathway towards achieving them (including by facilitating access to services) Active Families an exercise and nutrition programme designed for families. See – www.health. community-funded physical activity services and programmes specifically for Māori and Pacific communities, such as church groups, Zumba programmes and youth exercise programmes whānau-based programmes such as Triple P (Positive Parenting Program). Weight-loss drugs The weight-loss drug Orlistat promotes weight loss by blocking enzymes (lipases) that break down fats in the gut, preventing the absorption of fat, allowing it to pass through the body undigested. No weight loss drugs are registered for use with children and young people in New Zealand. Evidence update The United Kingdom National Institute for Health and Clinical Excellence (see NICE 2006 (revised 2014)) only recommends treatment with Orlistat in children aged 12 years and over if physical comorbidities (such as orthopaedic problems or sleep apnoea) or severe psychological comorbidities are present. Recommendations Practitioners should not use weight-loss drugs with children aged under 12 years, and are generally best avoided with young people.
Encourage appropriate (not food-related) rewards for when the child or young person meets a goal. Unmet goals can be viewed as opportunities for families to learn more about their situation, including the barriers they face to achieving their goals. Five key behavioural tools are: self-monitoring, stimulus control, problem solving, contingency management or contracting, cognitive restructuring. See Appendix 1 for more information on these tools. Other options for weight management Weight management support services and programmes Weight management services and programmes range from nutrition and healthy-eating services to exercise and weight-loss programmes. Some such services are publicly funded, through the Ministry of Health or DHBs. The types of services available vary throughout the country. Ideally, they should have input from a multidisciplinary team. Examples of relevant services and programmes include: dietetic services whānau planning services – Whānau Ora providers and collectives work to support whānau aspirations by helping whānau to set goals and creating a pathway towards achieving them (including by facilitating access to services) Active Families – an exercise and nutrition programme designed for families. See www.health. community-funded physical activity services and programmes specifically for Māori and Pacific communities, such as church groups, Zumba programmes and youth exercise programmes whānau-based programmes such as Triple P (Positive Parenting Program). Weight-loss drugs The weight-loss drug Orlistat promotes weight loss by blocking enzymes (lipases) that break down fats in the gut, preventing the absorption of fat, allowing it to pass through the body undigested. No weight loss drugs are registered for use with children and young people in New Zealand. Evidence update The United Kingdom National Institute for Health and Clinical Excellence (see NICE 2006 (revised 2014)) only recommends treatment with Orlistat in children aged 12 years and over if physical comorbidities (such as orthopaedic problems or sleep apnoea) or severe psychological comorbidities are present. Recommendations Practitioners should not use weight-loss drugs with children aged under 12 years, and are generally best avoided with young people.
clinical-guidelines-weight-management-nz-children-young-people-dec16.docx